New Phase 2 SYNAPSE-CMT Study to Test Effects of NMD670 in Charcot-Marie-Tooth Disease Type 1 and 2

Published Date: 21 Nov 2024

The phase 2 trial is expected to include 80 adults with genetically confirmed CMT who will be followed for a 21-day treatment period, using changes in functional assessments as the primary outcome.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Belgian Algorithm Reshapes Endometrial Cancer Care

2.

ASCO: Durvalumab plus FLOT beneficial for resectable gastric, GE junction cancer

3.

Nuclear missile workers are contracting cancer: They blame the bases

4.

On all CAR-T products, the FDA is calling for a new boxed warning.

5.

ASCO Future Focus: Metastatic Breast Cancer: Future Focus from the American Society of Clinical Oncology


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot